BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29593710)

  • 1. Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System.
    Ciabattini A; Pettini E; Fiorino F; Lucchesi S; Pastore G; Brunetti J; Santoro F; Andersen P; Bracci L; Pozzi G; Medaglini D
    Front Immunol; 2018; 9():380. PubMed ID: 29593710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomics of the Vaccine Immune Response: Priming With Adjuvant Modulates Recall Innate Responses After Boosting.
    Santoro F; Pettini E; Kazmin D; Ciabattini A; Fiorino F; Gilfillan GD; Evenroed IM; Andersen P; Pozzi G; Medaglini D
    Front Immunol; 2018; 9():1248. PubMed ID: 29922291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrapulmonary (i.pulmon.) Pull Immunization With the Tuberculosis Subunit Vaccine Candidate H56/CAF01 After Intramuscular (i.m.) Priming Elicits a Distinct Innate Myeloid Response and Activation of Antigen-Presenting Cells Than i.m. or i.pulmon. Prime Immunization Alone.
    Thakur A; Pinto FE; Hansen HS; Andersen P; Christensen D; Janfelt C; Foged C
    Front Immunol; 2020; 11():803. PubMed ID: 32457748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the Antigen-Specific CD4(+) T Cell Response Induced by Prime-Boost Strategies with CAF01 and CpG Adjuvants Administered by the Intranasal and Subcutaneous Routes.
    Ciabattini A; Prota G; Christensen D; Andersen P; Pozzi G; Medaglini D
    Front Immunol; 2015; 6():430. PubMed ID: 26379666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-Isotope SPECT/CT Imaging of the Tuberculosis Subunit Vaccine H56/CAF01: Induction of Strong Systemic and Mucosal IgA and T-Cell Responses in Mice Upon Subcutaneous Prime and Intrapulmonary Boost Immunization.
    Thakur A; Rodríguez-Rodríguez C; Saatchi K; Rose F; Esposito T; Nosrati Z; Andersen P; Christensen D; Häfeli UO; Foged C
    Front Immunol; 2018; 9():2825. PubMed ID: 30555488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide-specific T helper cells identified by MHC class II tetramers differentiate into several subtypes upon immunization with CAF01 adjuvanted H56 tuberculosis vaccine formulation.
    Prota G; Christensen D; Andersen P; Medaglini D; Ciabattini A
    Vaccine; 2015 Nov; 33(48):6823-30. PubMed ID: 26494626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll like-receptor agonist Pam
    Kennerknecht K; Noschka R; Löffler F; Wehrstedt S; Pedersen GK; Mayer D; Grieshober M; Christensen D; Stenger S
    Med Microbiol Immunol; 2020 Apr; 209(2):163-176. PubMed ID: 32020284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of Primary Immune Response by Different Vaccine Adjuvants.
    Ciabattini A; Pettini E; Fiorino F; Pastore G; Andersen P; Pozzi G; Medaglini D
    Front Immunol; 2016; 7():427. PubMed ID: 27781036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder.
    Thakur A; Ingvarsson PT; Schmidt ST; Rose F; Andersen P; Christensen D; Foged C
    Vaccine; 2018 May; 36(23):3331-3339. PubMed ID: 29699790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary Administration of the Liposome-Based Adjuvant CAF01: Effect of Surface Charge on Mucosal Adjuvant Function.
    Müllertz OAO; Andersen P; Christensen D; Foged C; Thakur A
    Mol Pharm; 2023 Feb; 20(2):953-970. PubMed ID: 36583936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection.
    Brown TH; David J; Acosta-Ramirez E; Moore JM; Lee S; Zhong G; Hancock RE; Xing Z; Halperin SA; Wang J
    Vaccine; 2012 Jan; 30(2):350-60. PubMed ID: 22075089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy Testing of H56 cDNA Tattoo Immunization against Tuberculosis in a Mouse Model.
    Platteel ACM; Nieuwenhuizen NE; Domaszewska T; Schürer S; Zedler U; Brinkmann V; Sijts AJAM; Kaufmann SHE
    Front Immunol; 2017; 8():1744. PubMed ID: 29312295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing the H56 Vaccine Delivered in 4 Different Adjuvants as a BCG-Booster in a Non-Human Primate Model of Tuberculosis.
    Billeskov R; Tan EV; Cang M; Abalos RM; Burgos J; Pedersen BV; Christensen D; Agger EM; Andersen P
    PLoS One; 2016; 11(8):e0161217. PubMed ID: 27525651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal boosting of H56:CAF01 immunization promotes lung-localized T cells and an accelerated pulmonary response to Mycobacterium tuberculosis infection without enhancing vaccine protection.
    Woodworth JS; Christensen D; Cassidy JP; Agger EM; Mortensen R; Andersen P
    Mucosal Immunol; 2019 May; 12(3):816-826. PubMed ID: 30760832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
    Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV
    Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
    Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
    PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosis.
    Nandakumar S; Kannanganat S; Dobos KM; Lucas M; Spencer JS; Amara RR; Plikaytis BB; Posey JE; Sable SB
    Sci Rep; 2016 May; 6():25837. PubMed ID: 27173443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost.
    Apostólico Jde S; Boscardin SB; Yamamoto MM; de Oliveira-Filho JN; Kalil J; Cunha-Neto E; Rosa DS
    PLoS One; 2016; 11(1):e0145637. PubMed ID: 26727218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against
    Kou Y; Wan M; Shi W; Liu J; Zhao Z; Xu Y; Wei W; Sun B; Gao F; Cai L; Jiang C
    J Microbiol Biotechnol; 2018 Jun; 28(6):1022-1029. PubMed ID: 29847865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.